Taken together, these results suggested that an ADC targeting nectin-2 could be useful in the treatment of ovarian cancer, as well as other nectin-2-positive cancers, including breast, colon, and lung cancers [22]. Here, NECTIN2 is linked to ovarian carcinoma.